{"schema_version":"secwatch.filing_event.v1","accession":"0001567892-24-000007","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.646787+00:00","generated_at":"2026-06-04T07:51:20.961540+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mallinckrodt FY2023 net sales $1.87B, EBITDA $572M; guides FY2024 EBITDA $520-560M","bullets":["FY2023 net sales $1.866B, down 2.5% YoY; Q4 net sales $469.3M (-4.1%).","FY2023 Adjusted EBITDA $571.9M, above guidance range; Q4 EBITDA $123.8M vs $175.5M.","Specialty Brands Q4 net sales $270.7M (-15.6%); impacted by Amitiza generic competition.","Specialty Generics Q4 net sales $198.6M (+17.8%); strong finished-dosage demand.","2024 guidance: net sales $1.80-1.90B, Adj. EBITDA $520-560M; FDA approved SelfJect injector."],"urls":{"canonical":"https://secwatch.observer/filing/0001567892-24-000007","json":"https://secwatch.observer/filing/0001567892-24-000007.json","markdown":"https://secwatch.observer/filing/0001567892-24-000007.md","text":"https://secwatch.observer/filing/0001567892-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/0001567892-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/mnk-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:51:20.961540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a79d59c1c2f947677045eb282bb899d750371a63","claim":"Keenova Therapeutics plc updated its the fourth quarter and fiscal year ended December 29, 2023 guidance (raised).","evidence_excerpt":"On March 26, 2024, Mallinckrodt plc provided its financial results for the three months and year ended December 29, 2023 as set forth in the attached Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000007/0001567892-24-000007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 29, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}